5 Things Amgen, Inc. Wants You to Know
Amgen may have crushed Wall Street's Q3 forecast, but if you didn't listen to its quarterly conference call, then you probably missed out on these key points concerning its long-term outlook.
Did Valeant Pharmaceuticals Make Another Bad Bet?
A slow start to sales for Addyi is the latest news to disappoint investors.
Why Horizon Pharma Is Crashing Today
The termination of a specialty pharmacy that distributes its drugs from a major drug payer's network is forcing shares lower.